NDAORAL-21TABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
NORLESTRIN 21 1/50 (ethinyl estradiol; norethindrone acetate) by Pfizer. Approved for pregnancy.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLESTRIN 21 1/50 is an oral combined hormonal contraceptive containing ethinyl estradiol and norethindrone acetate, indicated for pregnancy prevention. It is a 21-day tablet formulation that works by suppressing ovulation through estrogen and progestin receptor agonism. This product is currently in pre-launch stage under Pfizer sponsorship.
Pre-Launch
Pre-launch stage indicates small core team focused on regulatory clearance and market preparation; career opportunity limited until launch approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
NORLESTRIN 21 1/50 presents limited career opportunity at pre-launch stage with zero linked job postings. Roles will emerge post-approval, focusing on commercial execution in a highly competitive, mature contraceptive market with substantial generic and branded competition.
Brand Manager
Worked on NORLESTRIN 21 1/50 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.